Edition:
United Kingdom

FibroGen Inc (FGEN.OQ)

FGEN.OQ on NASDAQ Stock Exchange Global Select Market

64.60USD
18 Jul 2018
Change (% chg)

$-1.10 (-1.67%)
Prev Close
$65.70
Open
$65.45
Day's High
$65.45
Day's Low
$64.40
Volume
8,287
Avg. Vol
166,723
52-wk High
$68.15
52-wk Low
$33.10

Chart for

About

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.... (more)

Overall

Beta: --
Market Cap(Mil.): $4,359.11
Shares Outstanding(Mil.): 78.97
Dividend: --
Yield (%): --

Financials

  FGEN.OQ Industry Sector
P/E (TTM): -- 85.36 32.76
EPS (TTM): -1.92 -- --
ROI: -28.39 2.21 14.61
ROE: -58.84 3.85 16.34

BRIEF-FibroGen Reports Q1 Loss Per Share $0.50

* Q1 EARNINGS PER SHARE VIEW $-0.51 -- THOMSON REUTERS I/B/E/S

09 May 2018

BRIEF-Fibrogen Inc CEO's 2017 Compensation Was $7.1 Million

* FIBROGEN INC SAYS CEO THOMAS B. NEFF'S 2017 TOTAL COMPENSATION WAS $7.1 MILLION VERSUS $5.2 MILLION IN 2016 – SEC FILING Source text (https://bit.ly/2Hpk39x) Further company coverage:

24 Apr 2018

BRIEF-FibroGen Gets FDA Fast Track Designation For Its Pancreatic Cancer Treatment

* UPDATE - FIBROGEN GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR PAMREVLUMAB TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER

01 Mar 2018

BRIEF-Fibrogen Granted Fast Track Designation By U.S. FDA For Pamrevlumab Treatment Of Patients

* FIBROGEN GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR PAMREVLUMAB TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

01 Mar 2018

BRIEF-FibroGen Q4 Loss Per Share $0.27

* FIBROGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

27 Feb 2018

Earnings vs. Estimates